Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

Novartis

Overview

This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Hypertension

Interventions

Valsartan+/- HydrochlorothiazideDRUG

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hypertension that have newly started using Valsartan+/-HCTZ Exclusion Criteria: * Pregnancy or Hypersensitivity to Valsartan+/-HCTZ Other protocol-defined inclusion/exclusion criteria may apply

Locations (1)

Novartis Investigative Site

Singapore, Singapore

Outcomes

Primary Outcomes

Compliance rate at month 3, 6 and post study month 1 will be assessed by pill count

Secondary Outcomes

Patient Adherence to study/follow up visits -Clinical Outcome Measurement: Mean sitting systolic BP and mean sitting diastolic BP -Patient's and Physician's Satisfaction Survey

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.